Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Level 1 - systematic review of randomized trials
Individual participant data meta-analysis of 26 randomized controlled trials
PubMed 21067804 · doi:10.1016/S0140-6736(10)61350-5
What was done
Meta-analysis of individual participant data from randomized trials with at least 1,000 participants and at least 2 years of follow-up. The analysis evaluated 5 trials comparing more versus less intensive statin regimens (39,612 participants; median follow-up 5.1 years) and 21 trials comparing statin versus control (129,526 participants; median follow-up 4.8 years). Proportional risk reductions overall and per 1.0 mmol/L reduction in LDL cholesterol at 1 year post-randomization were calculated.
What was found
In more versus less intensive statin trials, an additional 0.51 mmol/L reduction in LDL cholesterol at 1 year produced a 15% further reduction in major vascular events (95% CI 11–18; p<0.0001), consisting of reductions in coronary death or non-fatal myocardial infarction (13%, 95% CI 7–19; p<0.0001), coronary revascularization (19%, 95% CI 15–24; p<0.0001), and ischaemic stroke (16%, 95% CI 5–26; p=0.005). Across all 26 combined trials, each 1.0 mmol/L LDL reduction resulted in: - Major vascular events: RR 0.78 (95% CI 0.76–0.80; p<0.0001), consistent across all patient subgroups including baseline LDL <2.0 mmol/L. - All-cause mortality: RR 0.90 (95% CI 0.87–0.93; p<0.0001), primarily driven by reductions in coronary heart disease death (RR 0.80, 99% CI 0.74–0.87; p<0.0001) and other cardiac deaths (RR 0.89, 99% CI 0.81–0.98; p=0.002). - Stroke mortality (RR 0.96, 95% CI 0.84–1.09; p=0.5) and other vascular deaths (RR 0.98, 99% CI 0.81–1.18; p=0.8) were unchanged. - Cancer mortality (RR 0.97, 95% CI 0.92–1.03; p=0.3) and cancer incidence (RR 1.00, 95% CI 0.96–1.04; p=0.9) showed no significant differences.
Why it matters
This establishes a linear, threshold-free benefit of LDL lowering on cardiovascular events and all-cause mortality, showing that more intensive statin therapy delivers proportional clinical benefits even in patients with low baseline LDL levels.
Limits
Limited to statin-based regimens and cannot be directly generalized to non-statin lipid-lowering agents from these data alone. Specific non-cancer adverse effects associated with high-dose statins (e.g., new-onset diabetes, liver enzyme elevations, or myopathy) are not reported in the abstract.
Cited by
- supports Clinical trial data demonstrate that the lower LDL cholesterol is reduced, the greater the cardiovascular protection.